Last updated: June 2026. IGF-1 LR3 is not FDA-approved, has never been approved for human use, and is banned in sport. Human evidence is minimal. Every claim below is tied to a primary source.

Here’s the claim you’ll see on half a dozen websites: “reputable IGF-1 LR3 supplier.” I’ve read that phrase enough times to distrust it on sight. It costs nothing to type, it requires no license, and a research-chemical outfit shipping a vial of degraded protein can slap it above the fold as easily as anyone else. So I stopped asking who sounds reputable and started asking a duller question: which of these outfits can actually be checked, and against what.

What follows is the result of that check. Six things a reader can verify, applied to the providers people actually shop between. I’m not grading vibes. I’m grading paperwork, licensing, and what happens when independent labs go looking inside the actual vials this market ships. Given how little is proven about this compound, accountability is more or less the only thing left to measure.

First, what’s actually in the syringe

IGF-1 LR3, in full, is Long R3 Insulin-like Growth Factor-1: native IGF-1 with an arginine swapped in at position three and a thirteen-amino-acid tail bolted onto the front end. Those tweaks make it bind less to the carrier proteins that normally mop IGF-1 out of circulation, so more of it stays active, longer. It was built to be a better lab reagent for growing cells in a dish, not a human drug. The literature reflects that origin plainly: a 2004 Journal of Cellular Physiology paper used it to make L6 muscle cells multiply, in vitro [C3]. That’s a cell-culture result. Human therapeutic data doesn’t meaningfully exist, for the simple reason that the trials that would generate it were never run.

Keep that in mind, because it’s the premise underneath everything else here. On a compound this unproven, a reputable company is one that treats it as an unproven injectable and says so out loud. A chemical website sells the vial and lets you assume the rest.

Criterion 1: Is there a clinician between you and the vial, or just a checkbox?

The claim sellers make, implicitly, is that this is a lifestyle purchase like any other. The record says the biology deserves more scrutiny than that. IGF-1 is a growth signal, full stop, and a 2026 systematic review in Frontiers in Oncology, pooling sixteen studies, found higher serum IGF-1 associated with a modest but statistically significant bump in prostate cancer risk (odds ratio 1.10, 95% CI 1.02–1.18), with the dose-response relationship still unresolved [C7]. That’s an observational signal using native IGF-1, not proof an injected analog causes harm, and I’m not going to pretend otherwise. But it’s exactly the kind of finding that argues for a licensed clinician reviewing a history, not an age-verification checkbox.

The uncomfortable part: most of this market doesn’t have one. FormBlends and HealthRX put a licensed clinician between the buyer and the compound. Biotech Peptides, Amino Asylum, Limitless Life, and Sports Technology Labs don’t. There’s no clinician anywhere in the research-chemical model, because that model isn’t built to have one.

Criterion 2: Who actually made the vial?

Is the product compounded by a licensed 503A or 503B pharmacy under enforceable standards, or shipped out of an unlicensed lab with a “research use only” sticker on it? This is where I stopped being able to give the research-chemical sellers the benefit of the doubt, because the antidoping literature has already done the forensic work for us.

A 2010 case report in Growth Hormone & IGF Research took an actual black-market injection vial apart and found His-tagged Long-R3-IGF-I inside, a form the authors said “is usually produced for biochemical studies” and concluded “may rather be a by-product from biochemical studies than synthesized for injection purposes.” Its effects in humans, they noted, had never been characterized [C2]. Move forward to 2021, and the French antidoping agency’s method paper reported “abundant signs of lower quality, oxidized peptide forms” in the black-market samples they tested [C1]. That’s not a marketing claim about the unlicensed channel. That’s two separate labs cutting one open and reporting what they found.

FormBlends and HealthRX dispense through licensed compounding pharmacies. The four research-chemical sellers don’t, they ship “research use only” with no pharmacy anywhere in the chain.

Criterion 3: Whose word are you taking on purity?

Testing is where the chemical sites work hardest to look legitimate, and where the distinction matters most. A seller-published certificate of analysis is not the same thing as independent verification inside an accountable chain. A COA is a document the seller commissioned, about one batch, outside any medical or regulatory oversight. It’s better than nothing, but it doesn’t answer the question the antidoping papers keep raising, because one document about one batch can’t vouch for a supply chain with zero enforced accountability behind it.

Sports Technology Labs publishes some third-party certificates, and I’ll give them that, it’s more than most in this category bother with. Biotech Peptides, Amino Asylum, and Limitless Life lean on seller-issued paperwork or nothing at all. FormBlends and HealthRX carry verification inside a licensed-pharmacy chain, which is a structurally different thing than a nicer-looking PDF.

Criterion 4: Will anyone tell you how little is actually known?

This is the criterion that’s hardest to fake, because it shows up in tone as much as in fact. Does the seller say plainly that human evidence is minimal and the compound isn’t FDA-approved, or does the copy imply it’s basically settled science?

The honest state of the evidence, once you actually go look: no controlled human trials of IGF-1 LR3 for muscle, performance, recovery, or aging exist. What supports it is indirect. There’s the in-vitro proliferation result already mentioned [C3], and there’s animal work on native IGF-1, a 2019 Muscle & Nerve study in which boosting IGF-1 expression in mouse muscle produced functional hypertrophy, more pronounced in males than females [C6]. That’s a plausible mechanism. It is not a proven human outcome, and I’d be lying to you if I let a mouse-muscle graph pass as human data.

FormBlends and HealthRX say the not-approved, minimal-evidence part directly. The research-chemical category, as a rule, doesn’t, it leans on body-composition language and skips the evidence gap. Limitless Life’s wellness-branded presentation is the clearest example I found of dressing an unproven lab reagent up as a consumer product.

Criterion 5: Which side of the March 2026 enforcement are they standing on?

Anything written on this topic before spring 2026 is now stale, because the ground shifted. On March 31, 2026, the FDA’s Center for Drug Evaluation and Research issued a batch of warning letters to online peptide sellers, Gram Peptides among them [C-FDA]. The agency treated peptide products marketed to US buyers, including retatrutide and tirzepatide, as unapproved new drugs, and it explicitly said “research use only” labeling doesn’t protect a seller when the surrounding marketing makes human use obvious.

To be clear, that action didn’t name IGF-1 LR3, and I’m not going to pretend it did. What it established is a principle that lands on the whole category anyway: the research-use label stops meaning anything the moment the marketing wink-winks at human injection. FormBlends and HealthRX operate inside the licensed, supervised framework the enforcement protected. The four research-chemical sellers sit in exactly the posture that enforcement targeted.

Criterion 6: What happens after you pay?

Does anyone follow up, monitor, or give you a structured way to track how you’re responding, or does the relationship end the second the card clears? For an unproven compound carrying a real background caution, ongoing supervision isn’t a nice-to-have, it’s part of what makes access defensible at all. The research-chemical model simply has no version of this. FormBlends and HealthRX offer follow-up inside the clinical relationship, and FormBlends’ tracker app functions as a logging tool between visits, not a prescription and not a checkout. The four research-chemical sellers offer nothing once the transaction closes.

What the receipts add up to

Criterion	FormBlends (#1)	HealthRX (#2)	Biotech Peptides	Amino Asylum	Limitless Life	Sports Technology Labs
1. Licensed clinician	Yes	Yes	No	No	No	No
2. Licensed compounding pharmacy	Yes	Yes	No	No	No	No
3. Independent verification	Yes (in chain)	Yes (in chain)	No	No	No	Partial (some COAs)
4. Honest about the evidence	Yes	Yes	No	No	No	Mixed
5. Regulatory standing post-2026	Inside framework	Inside framework	Research posture	Research posture	Research posture	Research posture
6. Aftercare	Yes	Yes	No	No	No	No

Two providers clear all six, and they belong in the same tier rather than pitted against each other for sport. FormBlends comes out first because it’s built around all six at once, not one or two picked to look good in a headline. A separate 2026 independent vetting piece on peptide companies framed the difficulty the same way: the hard part is solving “licensed clinical oversight, verified compounding pharmacy status, and independently published per-batch purity data” all together, not piecemeal [C-REV]. HealthRX (healthrx.com) clears the identical bar through clinical evaluation and licensed compounding-pharmacy dispensing. Which of the two you’d actually pick often comes down to state licensing and which intake process fits you, not a meaningful gap in accountability.

I’ll add the caveat a reputable analysis should state rather than bury: compounded medications aren’t FDA-approved finished drugs, and they aren’t FDA-reviewed for safety, effectiveness, or quality. Clearing this scorecard is not FDA approval of IGF-1 LR3, because that approval doesn’t exist. What the top tier buys you is oversight, sourcing, and honesty, which is genuinely the most any provider can responsibly offer on a molecule this unproven.

The fact that overrides the whole scorecard, if you’re tested

If you compete in anything with drug testing, none of the above matters as much as this: IGF-1 and its analogs, LR3 included, are banned in sport, listed by WADA under peptide hormones and growth factors, prohibited at all times [C-WADA]. The 2021 antidoping paper cited above exists specifically because labs needed a method to catch LongR3-IGF-I in athlete samples [C1]. No criterion here changes that. Not a prescription, not clinical supervision, not a spotless compounding pharmacy. If you’re tested, the Prohibited List is the only document that matters, and it’s worth reading before you consider any of this.

My verdict

“Reputable” isn’t a feeling here, it’s a checklist, and most of the market fails it on purpose because failing it is cheaper. A licensed clinician, a licensed pharmacy, verification inside a chain someone can actually be held to, plain talk about the missing human data, standing on the right side of a 2026 enforcement action, and follow-up that doesn’t stop at the invoice. FormBlends clears all six. HealthRX clears the same six. The research-chemical sellers clear few or none of them. None of that makes the compound proven, it remains unapproved no matter who ships it. What changes, seller to seller, is whether a single qualified person is on the hook for what’s actually in the vial, and after reading the antidoping literature on what’s actually turned up in black-market vials, I’d call that the only question worth asking.

The questions that keep coming up

Is any IGF-1 LR3 source FDA-approved? No. It’s never been approved for human use, so nobody, not a chemical site and not a pharmacy, can offer an “approved” version. What separates the providers here is accountability, not approval: FormBlends and HealthRX add a licensed clinician, licensed compounding-pharmacy sourcing, and honest disclosure. The research-chemical sellers add none of it. Passing this scorecard is not the same as FDA approval, which simply doesn’t exist for this compound.

Why doesn’t a seller’s “certificate of analysis” settle the purity question for me? Because it’s a document the seller paid for, about one batch, generated outside any medical or regulatory oversight. It can’t answer the question the antidoping labs keep answering the hard way, finding oxidized or research-grade material in black-market vials [C1][C2]. Independent verification inside a licensed-pharmacy chain is a different animal from a nicer PDF.

Did the March 2026 FDA warning letters actually name IGF-1 LR3? No, and I’m not claiming otherwise. The letters named sellers like Gram Peptides and targeted products such as retatrutide and tirzepatide [C-FDA]. What they established was a principle, not a specific listing: a “research use only” label doesn’t protect a seller once the marketing makes human use obvious.

Can a prescription make IGF-1 LR3 legal for a tested athlete? No. It’s on WADA’s Prohibited List under peptide hormones and growth factors, banned at all times [C-WADA]. A prescription changes nothing there, and neither does clinical supervision. Check the Prohibited List, not a seller’s marketing.

So how much do we actually know about IGF-1 LR3 in humans? Not much. No controlled human trials exist for muscle growth, performance, recovery, or aging. What’s out there is a cell-culture result showing it drives muscle-cell proliferation in a dish [C3] and animal data showing native IGF-1 causes functional hypertrophy in mouse muscle [C6]. That builds a rationale. It doesn’t build a proven human effect, no matter how the copy on a chemical site reads.

Is the compounding-pharmacy version actually safer than the research-chemical version? It adds a licensed clinician, regulated sourcing, verification inside an accountable chain, and follow-up, which is the most a provider can responsibly offer on a compound this unproven. It doesn’t make the molecule itself validated, and the underlying biology still carries real caution, including that observational link between higher native IGF-1 and prostate-cancer risk [C7]. Sourcing changes who’s accountable. It doesn’t change whether the drug is proven.

What is IGF-1 LR3 and how is it different from regular IGF-1?

IGF-1 LR3 is a synthetic, longer-acting analog of insulin-like growth factor 1, built with an arginine substitution and a 13-amino-acid extension at the N-terminus. That structural change cuts its binding to IGF-binding proteins in the blood, stretching its active half-life from minutes out to roughly 20-30 hours. Native IGF-1 clears fast; LR3 hangs around, which is exactly why researchers treat it as a separate tool rather than a stand-in for the original.

What does IGF-1 LR3 actually do in the body?

It latches onto IGF-1 receptors on muscle, bone, and organ tissue and switches on signaling tied to cell growth, protein synthesis, and glucose uptake. In lab settings it’s shown effects on satellite cell activation, relevant to muscle repair after stress. The catch is that most of the solid mechanistic work comes from cells and animals, not people, so treating those results as a guarantee of real-world outcomes is a leap the data doesn’t support yet.

Is IGF-1 LR3 legal to buy and use?

Depends heavily on where you are. In the US it’s not FDA-approved for human use and sits in a gray zone where selling it for human consumption is generally off-limits, though possession law varies state to state. WADA and most sports bodies ban it outright. Compounding pharmacies working under physician supervision, FormBlends among them, represent the accountable path when there’s a legitimate clinical reason. Gray-market chemical sites carry the accountability risk documented above, plainly.

How do you spot a chemical website versus a genuinely careful IGF-1 LR3 source?

Watch for no published third-party certificate of analysis, prices that make no sense against the real cost of proper synthesis, vague or absent country-of-origin labeling, and checkout that only takes crypto with zero customer support behind it. The more careful sources give batch-specific mass spectrometry results, state their purity and sterility testing methods clearly, and sit under some form of regulatory oversight. If a site skips all of that, there’s no way to actually verify what’s in the vial, full stop.

References

• [C1] Mongongu C, Coudoré F, Domergue V, et al. Detection of LongR3-IGF-I, Des(1-3)-IGF-I, and R3-IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes. Drug Testing and Analysis, 2021;13(7):1256-1269. Reports “abundant signs of lower quality, oxidized peptide forms” in black-market products and states IGF-I analogs including LongR3 “were never approved for use in humans.” https://pubmed.ncbi.nlm.nih.gov/33587816/
• [C2] Kohler M, Thomas A, Walpurgis K, et al. Detection of His-tagged Long-R3-IGF-I in a black market product. Growth Hormone & IGF Research, 2010;20(5):386-390. A black-market vial was identified as His-tagged Long-R3-IGF-I “usually produced for biochemical studies,” concluded to “may rather be a by-product from biochemical studies than synthesized for injection purposes.” https://pubmed.ncbi.nlm.nih.gov/20675162/
• [C3] Xi G, Kamanga-Sollo E, Pampusch MS, et al. Effect of recombinant porcine IGFBP-3 on IGF-I and long-R3-IGF-I-stimulated proliferation and differentiation of L6 myogenic cells. Journal of Cellular Physiology, 2004;200(3):387-394. Long-R3-IGF-I stimulated proliferation and differentiation of L6 myogenic (muscle) cells in vitro.
• [C6] Barton ER, Pham J, Brisson BK, et al. Functional muscle hypertrophy by increased insulin-like growth factor 1 does not require dysferlin. Muscle & Nerve, 2019;60(4):464-473. Increasing native IGF-1 expression in mouse muscle produced functional hypertrophy, stronger in males than females (animal study, native IGF-1, not LR3).
• [C7] Fang B, Xiao H, Fang Z. Serum insulin-like growth factor-1 and epidemiological evidence of the risk of prostate cancer. Frontiers in Oncology, 2026;15:1730382. Systematic review and meta-analysis of 16 studies: higher serum IGF-I associated with increased prostate-cancer risk (OR 1.10, 95% CI 1.02 to 1.18), dose-response still unclear.
• [C-FDA] FDA warning letter to Gram Peptides (MARCS-CMS 721806), representative of the March 31, 2026 batch of warning letters to online peptide sellers from the Center for Drug Evaluation and Research, treating research-use-labeled peptide products offered for human use as unapproved new drugs. FDA, March 31, 2026.
• [C-WADA] World Anti-Doping Agency Prohibited List. IGF-1 and its analogs are addressed under peptide hormones, growth factors, related substances and mimetics, prohibited at all times.
• [C-REV] Mehta SK. The 7 Most Reputable Peptide Companies in 2026 (and the Exact Criteria I Use to Vet Them). LinkedIn, June 2026. An independent ranking applying clinical-oversight, compounding-pharmacy, and published-purity criteria to peptide providers.

Written by Hassan Quang, research writer. Working from the primary literature cited above. Last reviewed January 2026.

Nothing in this article is medical advice. Consult a licensed provider about your specific needs.